September 19 - 20, 2019

2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Hilton Garden Inn Philadelphia Center City
45+
Speakers
250+
Attendees
7
Sessions

The next step towards changing treatment paradigms in immuno-oncology

The current revolution in immuno-oncology is being driven by Antibody Drug Conjugates, Immune Checkpoint Inhibitors, Bispecific Antibodies and Cell Therapies. Clinical trials have showed that cancer patients can tolerate this immune-based treatment more effectively than conventional treatments like chemotherapy and radiotherapy. It’s clearly one of the hottest fields of Biopharma which has gained momentum in the past few years.

users

With more than 45 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy  

users

Meet and network with experts from leading universities and industry sharing their knowledge on Preclinical and Translational Immuno-Oncology Developments, Next Gen CAR-T Cell Therapy, Immune Checkpoint Inhibitors, Monoclonal and Bispecific Antibodies and more.

users

A platform to meet experts from Pharma, bio-pharma and biotech companies and increase your learning in Monoclonal and Bispecific Antibodies, Cell Therapy and Immune Checkpoint Inhibitors.

After our successful edition last year, we are coming up with the “2nd Annual MarketsandMarkets Next-Gen Immuno-Oncology Congress” on 19-20 September, Philadelphia, USA which will gather academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy.

WHAT TO EXPECT
Key Highlights
  • Updates in development of monoclonal Abs and bispecific Abs
  • Immune Checkpoint Inhibitors and Combinations
  • Preclinical and Translational Immuno-Oncology Developments
Sessions
  • Targeted Antibodies and Combinations
  • Pre-clinical & Translational Immuno-Oncology Developments
  • New Antibody Formats
  • New Immune Checkpoints for Immunotherapy
Why Attend
  • Find out new case studies of antibody projects in development
  • Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
CONFERENCE AGENDA
CONFERENCE SPEAKERS
Advisors
Rakesh Dixit

Rakesh Dixit

CEO
Bionavigen

Rakesh Dixit

CEO
Bionavigen
Stefan Glueck

Stefan Glueck

Senior Vice President, Global Medical Affairs
Celgene

Stefan Glueck

Senior Vice President, Global Medical Affairs
Celgene
Speakers
Shailendra Singh (Shelly)

Shailendra Singh (Shelly)

Chief Operating Officer
MarketsandMarkets

Shailendra Singh (Shelly)

Chief Operating Officer
MarketsandMarkets
Roy Baynes

Roy Baynes

Senior Vice President
Merck

Roy Baynes

Senior Vice President
Merck
Rakesh Dixit

Rakesh Dixit

CEO
Bionavigen

Rakesh Dixit

CEO
Bionavigen
Stefan Glueck

Stefan Glueck

Senior Vice President, Global Medical Affairs
Celgene

Stefan Glueck

Senior Vice President, Global Medical Affairs
Celgene
Shahram Salek-Ardakani

Shahram Salek-Ardakani

Senior Director, Cancer Immunology
Pfizer

Shahram Salek-Ardakani

Senior Director, Cancer Immunology
Pfizer
Carl Morrison

Carl Morrison

President, Chief Medical Officer
OmniSeq

Carl Morrison

President, Chief Medical Officer
OmniSeq
Emmanuel Normant

Emmanuel Normant

Vice President, Preclinical Sciences
TG Therapeutics

Emmanuel Normant

Vice President, Preclinical Sciences
TG Therapeutics
Vicki Plaks

Vicki Plaks

Translational Lead, Principal Scientist, Translational Sciences
Kite Pharma

Vicki Plaks

Translational Lead, Principal Scientist, Translational Sciences
Kite Pharma
SPONSORS
Gold
example-image

BIOCYTOGEN

Sponsors & Exhibitors
example-image

Myriad RBM

example-image

TransCure bioServices

example-image

Nebion

example-image

Flagship Biosciences

example-image

PromoCell

example-image

Alloplex

example-image

HistologiX

PARTNERS
Supporting Association
BioPartner UK

BioPartner UK

Media Partners
example-image

SciDoc Publishers

example-image

Technology Networks

example-image

GEN

example-image

PharmaTutor

example-image

PharmaVOICE

example-image

GenomeWeb

LOCATION
Hilton Garden Inn Philadelphia Center City

Please contact us on events@marketsandmarkets.com to get hotel booking link.

About the Hotel

Opposite the Pennsylvania Convention Center, this understated hotel is a 16-minute walk from Independence National Historical Park and a mile from Rodin Museum. 

Down-to-earth rooms and suites offer free Wi-Fi, flat-screen TVs and microwaves, plus minifridges and Keurigs. Some have separate living areas, pull-out sofas and/or dining areas.

Amenities include a restaurant, a bar and coin-operated laundry facilities. There's also a gym, meeting space and a bright lounge with a fireplace, plus an indoor pool and a hot tub. Breakfast and parking are available (fee).

For any queries regarding the hotel booking please write to us at events@marketsandmarkets.com

Hotel Booking Link

You will receive a link to book your accommodation via email once you are fully registered. (Please note that we do not authorize any 3rd party agencies (e.g. Exhibitors Housing Management) to book on our behalf and, occasionally, companies fraudulently try to represent us. If you are contacted by anyone other than us regarding your accommodation requirements for this event, please let us know immediately on events@marketsandmarkets.com

NEWS
Card image cap

According to a statement by the VP of Roche technical development bioprocessing, Wolfgang Kuhne said that the older processes used to produce monoclonal antibodies like Herceptin and Avastin are not sufficient to produce complex and advanced pharmaceuticals. Read more.....

Card image cap

Johnson & Johnson and Zymeworks have done a deal by which Johnson & Johnson will pay Zymework $50m to license it as well as to develop around six therapeutic agents. Jansen will have all the ownership and responsibilities for all research development and commercialization of the outcome. According to Zymework’s CEO Ali Tehrani, the license is not exclusive for any targets To read more....

Card image cap

Genmab through collaboration with Blink biomedicals raised a whopping $503 Million through an American initial public offering (IPO) all this got revealed on Friday during an event. Genmab also launched an up to $200 million-per-product cancer therapy with Blink biomedicals. Read more...

PAST EVENT GALLERY